Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01861301 · OUTCOME

Incidence of Adverse Events, Graded Per NCI CTCAE Version 4

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma · Source last updated 2016-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Up to 2 years

What was measured

Grade 3 or higher AE of any type, regardless of attribution.

Groups in this outcome

Treatment (Tivantinib)

Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Tivantinib)18

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Tivantinib)22.2Not reported6.447.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.4
        upper Limit
        47.6
        value
        22.2
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Grade 3 or higher AE of any type, regardless of attribution.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Tivantinib)
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 2 years
title
Incidence of Adverse Events, Graded Per NCI CTCAE Version 4
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice